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ABSTRACT
Introduction: The past two decades have seen a revolution in the management of labor and delivery; rates of cesarean delivery (CD), medical 
induction, and electronic fetal monitoring have increased dramatically. CD occurs in one third of deliveries and is the most common inpa-
tient surgery. The increase in CD has occurred despite concerns about maternal complications (infection, blood loss, hysterectomy, uterine 
rupture) and racial disparities. Since 1993, black and white women have gone from comparable CD rates to rates 40% higher among black 
women compared to white women.
Methods: This project has assembled a cohort of over 800,000 deliveries from the Cerner Corporation’s Health Facts® database. Health 
Facts contains 63 million unique patients from over 600 U.S. healthcare facilities. Data include comprehensive clinical records from inpatient 
and outpatient encounters and includes data from pharmacy, laboratory, registration and billing data.
Results: CD was identified using a validated definition that incorporates International Classification of Disease (Version 9, Clinical Modifica-
tion) codes for delivery outcome and relevant diagnosis-related groups and procedures. We examined 618,582 singleton deliveries to black 
and white women and identified 177,564 cesarean deliveries (28.7%).
Conclusions: The rate of cesarean was higher for black women overall and during the years 2000 - 2006 and 2011 - 2015 the CD rate for 
black women was significantly higher than for white women. Of note, during the period from 2007 - 2010 rates of cesarean were similar 
among black and white women. The rate of repeat cesarean was lower among black women, while the rate of induction of labor was higher.
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ABSTRACT
Introduction: Ninety-five percent of all inmates are eventually released back into communities, with many being released without access 
to the most basic of necessities. Women in particular face complex health and social challenges – children, partners, strained employment 
opportunities, health problems – before incarceration that they must also face upon reentry. This poses a barrier to their successful reinte-
gration back into society.
Methods: The present study analyzes data collected as part of the sexual health empowerment (SHE Project) health literacy intervention. 
Participants were recruited from three county jails in the greater Kansas City area. At baseline, participants completed a survey that assessed 
sociodemographic characteristics and social histories prior to incarceration. Women were followed annually after program completion to 
complete surveys to assess their long-term health and social circumstances. The present study is a secondary analysis of baseline and follow-
up data.
Anticipated Results: We use Hobfoll’s Conservation of Resources (COR) Theory to conceptualize the stress that justice-involved women 
may experience as a result of perceived or actual loss of resources. We hypothesize that “loss spirals”, a term coined by Stevan Hobfoll, creates 
psychological stress that drives justice-involved women to assume risky sex and drug behaviors that will generate more resources and help 
to cope with the stress.
Significance of Impact: This study aims to define a succinct longitudinal timeline assessing biopsychosocial outcomes of women released 
from jail in order to improve prevention and intervention techniques for improvement in social and health circumstances of women leaving 
jail and their reduction in recidivism.
Funding Support: This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of 
Kansas Clinical and Translational Science Institute (#UL1TR002366). The contents are solely the responsibility of the authors and do not 
necessarily represent the official views of the NIH or NCATS.
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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer with a five-year survival rate ~7%. Thus, early detection 
could be key to reducing its mortality. Finding effective biomarkers is crucial to early detection. Pancreatic cancer biomarker studies typi-
cally consider more than two classes (i.e., recruited individuals that are either healthy, suffering from pancreatitis/cysts, or from aggressive 
PDAC). Conventional ROC curve analysis is the most popular tool to assess the discriminatory ability of biomarkers in distinguishing between 
two groups. For more than two groups, this approach is inadequate to determine decision cutoffs for decision-making purposes. Currently 
there is no accuracy-based statistical approach that is immune to the prevalence of the disease and is able to accommodate information from 
all three groups to optimally determine a decision rule for classification of patients. We propose a Euclidian distance-based approach as a 
method of estimating optimal cutoff values. We provide a full analysis framework when interest lies in decision-making and provide paramet-
ric and nonparametric approaches. Our approaches can easily be generalized into k-class problems when we are interested in distinguishing 
between four or more classes. We can extend our methods to consider the costs of incorrect decision making for each of the groups and weigh 
them accordingly. Additionally, combinations of biomarkers or relevant clinical information can also be accommodated straightforwardly to 
improve decision rules. We illustrate the usefulness of our approaches by analyzing a pancreatic cancer biomarker study conducted at the 
University of Texas MD Anderson Cancer Center.
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ABSTRACT
Introduction: To study breast cancer progression, we developed the Mouse-Intraductal (MIND) model which involves intraductal injection 
of breast cancer cells into the mammary ducts of immunocompromised mice, where they display a course remarkably similar to the evolution 
of human breast cancer, with the formation of lesions in situ followed by invasion into the surrounding stroma. More recently, we are collect-
ing peripheral blood from these same women and have been successful in humanizing mice with the patient’s own hematopoietic stem cells 
(HSC).
Preliminary Data: We have achieved successful engraftment of peripheral blood-derived and bone marrow-derived human CD34+ cells 
into NSG (immunodeficient NOD-SCID Il2rg-/-), MISTRG (immunodeficient Rag2-/-Il2rg-/- transgene SIRPa expressing GM-CSF, 
IL-3, M-CSF, TPO) and MISTRG6 mice (plus IL-6) and observed recruitment of their progenitors to breast cancer lesions. Our preliminary 
studies demonstrate preferential myeloid development when using peripheral blood derived CD34+ cells, while both myeloid and lymphoid 
development are achieved when using bone marrow derived CD34+ cells. Furthermore, MISTRG6 mice show improved development of both 
human myeloid and lymphoid hematopoietic cells compared to MISTRG and NSG mice. 
Impact and Future Aims: The major advantage of our model is the ability to observe progression of patient breast cancer and their associ-
ated immune cells in vivo. Analyzing patient samples eliminates the ability to track the progression of lesions and their associated immune 
cells in vivo. By maximizing these unique advantages, we hope our results will help guide individualized immunotherapy in future patient care.
Funding Support: This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of 
Kansas Clinical and Translational Science Institute (#UL1TR002366). The contents are solely the responsibility of the authors and do not 
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ABSTRACT
Introduction: Although causal linkage between hyperglycemia and decreased lung function in cystic fibrosis (CF) is unknown, it is thought 
to be related to excess inflammation and ion channel dysfunction.
Methods: We utilized complementary in vitro and in vivo approaches to assess the effects of hyperglycemia on the CF airway epithelium. 
In vitro: Primary CF bronchial epithelial (CFBE) cells at the air-liquid interface under hyperglycemic (HG; 255 mg/dL) or normoglycemic 
(NG; 100 mg/dL) conditions. Airway surface liquid (ASL) was measured by meniscus scanning and apical K+ (BK) ion channel current was 
measured in Ussing chambers. In vivo: In CF subjects with or without CF related diabetes (CFRD), glycemic control was measured using 
continuous glucose monitoring.
Results: Nasal epithelial cells were collected and analyzed by qPCR for the expression of RAGE, TGF-1, and LRRC26, the regulatory subunit 
of BK. Compared to normoglycemia, CFBE cells under hyperglycemia show significantly reduced ASL (68.4 ± 17.4 μL, NG vs. 51.5 ± 18.1 μL, 
HG; p<0.05), a significant decrease in BK activity (-10.6 ± 0.8 μA/cm2, NG vs. -1.6 ± 0.5 μA/cm2, HG), and a 69% increase in mRNA expres-
sion of RAGE (p<0.05). From our in vivo studies, CF patients with and without CFRD showed significant negative correlation between the 
mRNA expressions of TGF-1 and LRRC26 (R2=0.73, p<0.05).
Conclusions: In vitro data suggests hyperglycemia adversely affects airway hydration, in part, by impairing BK channel function. Reduc-
tion of LRRC26 expression in subjects with elevated TGF-1 and those with glycemic abnormalities point to BK as a target for therapeutic 
intervention in CFRD.
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ABSTRACT
The University of Kansas Medical Center – Genomics Core leveraged the Frontiers: KU Clinical and Translational Science Institute infra-
structure award to purchase an Eppendorf MasterCycler Pro thermal cycler and Countess II Automated Cell Counter to support the single 
cell initiative of the Genomics Core at KUMC. The MasterCycler Pro and Countess II are used to support the 10X Genomics Chromium 
Controller for performing the full suite of 10X Genomics single cell applications which include Single Cell 3’ Gene Expression, Single Cell 5’ 
Expression and V(D)J Enrichment and Single Cell ATAC – Chromatin Profiling.
The Countess II Automated Cell Counter is used to ensure that adequate cell counts and high viability of submitted samples are present. The 
Countess also allows visualization of any cellular debris or cell clumping which will interfere with a successful 10X emulsification procedure 
required for a successful single cell library preparation. The MasterCycler Pro has been sequestered to exclusively support single cell library 
preparations. The MasterCycler performs the initial single strand synthesis which incorporates the 10X GEM barcode and Unique Molecular 
Identifier (UMI), second strand synthesis and Illumina adapter ligation to complete the 10X library preparation.
These instruments have proven critical to the successful execution of 16 single cell projects in support of seven different investigators. Fron-
tiers’ investment in the single cell initiative has had a positive impact on cutting edge single cell expression and epigenetic research performed 
at the University of Kansas Medical Center.
Funding Support: This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of 
Kansas Clinical and Translational Science Institute (#UL1TR002366). The contents are solely the responsibility of the authors and do not 
necessarily represent the official views of the NIH or NCATS.
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ABSTRACT
Introduction: Alzheimer’s disease (AD) is the most common form of irreversible, progressive dementia that affects memory loss, cognitive 
capabilities, and behavior. Although, significant progress has been made to understand genetic and clinical risk factors associated with AD, 
our understanding of AD remains incomplete resulting in ineffective prevention or cure.
Methods: Several studies have indicated that the polymorphisms in the mitochondrial DNA (mtDNA) play an important role in the mecha-
nism of AD. Therefore, in order to understand the association of the mitochondrial genetic alteration with AD, we carried out cross-sectional 
association analysis using the clinical and mitochondrial single nucleotide polymorphism (SNP) data. We used the data collected at Universi-
ty of Kansas Alzheimer’s Disease Center (KU ADC) to carry out the analyses. We also used the data from Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) for the replication and validation analyses.
Results: The KU ADC data consists of 146 AD and 265 cognitively normal subjects, and ADNI data has 244 AD and 242 controls. For both 
datasets, the haplogroups information for each subject and APOE ε4 carrier status were also available.
Conclusions: We found that the rates of incidence of AD were statistically significantly different among the haplogroups, with differing 
strengths of association for different haplogroups. APOE ε4 was significantly associated with AD overall (p-value = 1.9×10-11) and the asso-
ciation varied by haplogroups (i.e., interaction). The results were consistent with the ADNI data. Our study has generated hypothesis and 
the data for further studies ahead to understand the etiology of AD.
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ABSTRACT
Introduction: Age-related bone loss and associated fracture risk is an increasing concern worldwide. Oxidative stress causes mitochondrial 
damage and is associated with age-related degeneration in many cell systems, including bone cells.
Methods: To understand mitochondrial function in bone cells in situ, live-cell and intravital imaging of mitochondrial NADH and mito-
chondrial morphology was performed using transgenic mice expressing GFP in osteocytes as well as in MLO-Y4 osteocyte-like cells and 
OmGFP66 cells, which model osteoblast-to-osteocyte transition. NADH excitation and emission spectra in live osteocytes and osteoblasts 
matched well with pure NADH, with maximal multiphoton excitation at 740 - 760nm, resulting in blue NADH autofluorescence. With 760nm 
excitation, maximal NADH emission occurred at 460nm. Metabolic challenge was performed with carbonylcyanide-3-chlorophenylhydra-
zone and sodium cyanide, which convert NADH to its maximally oxidized or reduced states.
Results: This showed that osteoblasts had a lower resting redox state, with 40% of their NADH in a reduced state, compared to osteocytes 
with 75 - 80%. Live imaging using mitotracker Red-CMXRos showed that osteocytes have fewer mitochondria, lower mitochondrial area 
and % area, and increased solidity.
Conclusions: These data show that osteocytes in vivo under normoxic conditions have significant levels of mitochondrial NADH and show 
differences in mitochondrial number, morphology and function compared to osteoblasts. These live-cell imaging techniques can be used 
to determine changes in mitochondrial function during aging/cellular senescence and disease. These studies were supported by Frontiers 
equipment funding, including a Tokai-Hit CO2 incubation system, Leica 16x and 20x objectives and Imaris9.2 software which are available 
to other investigators through the UMKC Confocal Imaging Core.
Funding Support: This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of 
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ABSTRACT
Introduction: Pancreatic cancer (PDAC) is the fourth leading cause of cancer-related deaths in the U.S. Gemcitabine remains the drug 
of choice for metastatic disease, but only little improvement is seen in survival rates. Hence, there is a dire need for novel therapeutics for 
PDAC. We found that PRLR is overexpressed in PDAC tissues and cell lines and knockdown of the receptor resulted in reduced tumor 
formation in mice. Hence, PRLR is a novel target for therapeutic interventions in PDAC.
Methods: As there is no small molecular inhibitor available for targeting the receptor, we developed a homology model of the intracellular 
domain of PRLR that encodes the JAK2 binding site, and then performed a virtual screening of small molecules using IDOCK and I-TASS-
ER servers. Using Fragment-based drug design, we derived commercially available compounds for virtual screening. We selected several 
compounds that came out of the virtual screening and performed in vitro proliferation assays in the PDAC cells. We identified antipsy-
chotic drugs including penfluridol that can inhibit the proliferation of PDAC cell lines. Moreover, pretreatment of these antipsychotic drugs 
inhibited PRL-induced STAT3 and ERK phosphorylation in PDAC cell lines. Further, we used cellular thermal shift assay and drug affinity 
binding assay to confirm the binding of Penfluridol and PRLR. We also used cell-free systems such as surface plasmon resonance (SPR) 
and magnetic relaxometry to confirm the drug binding. Moreover, Penfluridol treatment significantly decreased pancreatic tumor burden in 
animal models. In conclusion, we identified penfluridol is a potential drug candidate for targeting PRLR in PDAC.
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ABSTRACT
Introduction: Anorexia nervosa (AN) is a serious condition associated with numerous medical complications, psychiatric comorbidity, and 
the highest mortality rate of any psychiatric disorder. Relapse rates remain high and for many, AN becomes an enduring condition. The only 
reliable prognostic indicator for AN is “rapid response” (i.e., weight gain over the first four weeks of treatment). Yet, there are no reliable 
predictors of rapid response at baseline. There is a pressing need to identify novel neuro-markers that confer early risk for poor treatment 
outcome.
Methods: Study goals were to systematically identify potential neuro-markers related to short-term AN outcomes by assessing brain activa-
tion associated with delayed discounting (capacity to delay immediate gratification), sensitivity to food reward (responses to rewarding foods 
and decisions to choose palatable foods), and threat sensitivity (heightened reactivity to potential danger or harm). The purpose of this study 
was to identify neural predictors of short-term treatment response in adolescents with AN. Participants were adolescent females with AN 
who entered their first course of eating-disorder treatment within the past six months.
Specific aims: 1) Test neural activation during tasks measuring delayed discounting, food reinforcement, and threat and 2) Identify prospec-
tive associations of task-performance and task-based neural activation with eating-disorder symptoms at one-month follow-up.
Conclusions: Differentiating neurobiological processes that contribute to AN chronicity may lead to the development of prognostic indica-
tors at initial treatment presentation. These neuromarkers may improve clinical decision-making and allow providers to identify patients 
requiring more intensive treatment interventions to prevent chronicity and mortality.
Funding Support: This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of 
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ABSTRACT 
Introduction: Osteocytes are the primary mechanosensory cell in bone and activate β-catenin signaling in response to mechanical loading 
of bone.
Methods: In order to understand the mechanism by which osteocytes activate β-catenin signaling, we have developed a stably transfected 
osteocyte cell line that expresses luciferase when β-catenin signaling occurs in the nucleus. To quantitate luciferase activity, we purchased a 
VICTOR Nivo Multimode Plate Reader (Perkin-Elmer) with the support of Frontiers funding. This instrument quantitatively measures lucif-
erase activity (fluorescence and absorbance) in several plate formats, thus permitting high throughput screening of compounds that activate 
β-catenin signaling. We stably transfected the MLO-Y4 osteocyte-like cell line with the TOPflash vector pGL4.9[luc2P/TCF_LEFRE/Hygro] 
(Promega). Clone A3-F9 gave a dose response to increasing concentrations of Wnt3a (1-100ng/ml) and activation with 10mM LiCl gave the 
equivalent of a submaximal dose of Wnt3a (10ng/ml).
Results: We demonstrated that C2C12 myotubes, but not myoblasts, produce a factor that activates β-catenin signaling two-fold using these 
TOPflash-MLO-Y4 cells, but in combination with Wnt3a (10 ng/ml; 10-fold activation) produces a 20-30-fold increase in activity measured 
in our luciferase assay. We demonstrated that production of this factor by C2C12 myotubes is partially regulated by mTOR signaling. We are 
currently seeking to identify this factor using our TOPflash-MLO-Y4 cells.
Conclusions: The acquisition of the VICTOR Nivo Multiplate reader provides us the means to conduct a high throughput screening approach 
to identify this factor(s). This instrument is part of a Core in the UMKC School of Dentistry Department of Oral and Craniofacial Sciences 
and available to other investigators for their studies.
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ABSTRACT
Introduction: Initiation of JUUL use by young adults is one of the most significant issues of concern within the debate on vaping. Despite 
the proliferation of products and the surge in prevalence, no studies have investigated individual-level interventions or prevention strategies 
for pod-mod use.
Methods: Participants (N = 947) were young adults (< 30 years old) recruited from Amazon’s Mechanical Turk based on smoking (never, 
former, and current smokers) and JUUL use status (never and current users). In a pre-post design, participants completed baseline assess-
ments, were presented with a brief JUUL-specific educational intervention and completed post-assessment measures. Primary outcomes 
were changes in JUUL knowledge, perceived harmfulness, intentions for future use, and motivation to change.
Results: Participants (Mean age = 26.1) were male (57%) and White (75%). Overall, the intervention increased JUUL-related knowledge, 
risk perceptions, commitment to quitting, and readiness to quit JUUL (all p ≤ 0.001). Similarly, participants showed decreased interest in 
future JUUL use, interest in purchasing JUUL, and interest in future regular JUUL use (all p ≤ 0.001). There were significant Time X Group 
interactions for JUUL-related knowledge (p < 0.001), with never JUUL/never smokers showing the greatest increase in product knowledge 
following the intervention. However, no other interaction effects were significant.
Discussion: The intervention was effective in increasing knowledge and risk perceptions while reducing intentions for future use. The inter-
vention was most effective in increasing knowledge among non-users, suggesting that brief educational interventions may be useful tools for 
preventing pod-mod initiation while more intensive interventions may be necessary to alter attitudes and use behaviors among current users.
Funding Support: This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of 
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ABSTRACT
Introduction: American Indians (AI) have the highest rates of smoking and smokeless tobacco (SLT) use among all major racial/ethnic 
groups. There is limited information about the use of alternative tobacco (AT) products such as electronic cigarettes. The objective of this 
pilot study is to understand the knowledge, attitudes, beliefs, and behaviors (KABB) surrounding AT product use among AI college students.
Methods: We conducted 19 focus groups with AI college students age 18 and older. Participants were stratified by AT use, cigarette use, and 
never users of tobacco products. Focus groups were audio-recorded and transcribed verbatim in preparation for coding and standard text 
analysis. Participants completed a short survey that collected information on demographics and KABB about tobacco products. Surveys were 
analyzed with frequencies and measures of central tendencies.
Results: Participants included 105 AI college students. Participant’s mean age was 21 years and 50% were female. Focus groups ranged in size 
from two to nine. Related to e-cigarette use, participants cited flavors, discreteness, stress, and social aspects as factors for use. Survey results 
indicate that 35% of participants were current e-cigarette users, 30% were current smokers, and 9% were current SLT users.
Conclusion: This pilot study confirms that AI college students are following a similar trend to other racial/ethnic groups in terms of AT use. 
It is important that we obtain estimates of AT use and include AI in prevention and cessation efforts. This study will help develop appropriate 
prevention and cessation messaging for this population.
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ABSTRACT
Introduction: A proof of concept trial (NCT02914977) was designed to measure the ability of low dose DNR to inhibit pS552-β-catenin 
in LSCs of adult relapsed/refractory AML patients. A protocol amendment added a second cohort of patients with newly diagnosed AML 
undergoing standard chemotherapy with DNR and cytarabine (7+3 induction).
Methods: Treatment in each cohort consisted of DNR given at a dose of 6.75mg/m2/day x five days. Patients with relapsed/refractory AML 
had bone marrow aspiration pre-treatment prior to day 1, followed by DNR on days 1-5, and a post-treatment bone marrow aspiration on day 
8. Patients with newly diagnosed AML were treated with conventional 7+3 chemotherapy.
Results: A sample from the day 14 bone marrow was collected. DNR was given on days 15 - 19. Bone marrow aspiration was performed with 
blood count recovery and samples sent for LSC marker assessment.
Discussion: In this study, we will determine the safety, pharmacokinetics, and pharmacodynamic effects of low dose DNR. The LSC popula-
tion and phosphorylation status of β-catenin will be measured pre-and post-treatment. Two or more prior induction attempts are required 
for study entry for refractory patients; relapsed patients require only one prior induction. The trial completed its accrual goal of 18 patients. 
Low-dose DNR treatment was well-tolerated with no unexpected adverse events. In this pilot proof of concept trial, we will demonstrate the 
feasibility of serial bone marrow aspiration to measure biomarkers of LSC response.
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ABSTRACT
Introduction: American Indians (AI) are disproportionately and significantly impacted by disease morbidity, mortality and poor behavioral 
health outcomes. Based on data from the National Vital Statistics Reports, the leading cause of death among AI is cancer (19%), followed 
by heart disease (18%). Regionally, health disparities among AIs reflect national statistics. Health communication targeted to address these 
health disparities exist; however, few evidence-based strategies integrate holistic approaches. The impact of health communication research 
and practice is evolving and continues to emerge as a core part of health promotion. Strategies that appeal and increase persuasiveness of 
health messages are more likely to penetrate existing cultural beliefs and positively influence health behavior outcomes. The objective of this 
study was to explore how tribal and elder leaders throughout the Plains viewed themselves as health communicators within their communities.
Methods: Members of the Center for American Indian Community Health conducted 39 in-depth interviews from December 2017 to 
December 2018 with members of federally recognized tribes living in reservation communities, as well as urban tribal communities across 
the region.
Results: Results from this sample show that these individuals do not see themselves as the “authority” health communicator within their 
tribe and community. The term health promoter was viewed as problematic in Native communities for cultural reasons.
Conclusion: Overarching themes included seeing themselves as communicators of holistic health, specific health prevention programs, 
access, targeted communication and health promoters as a collective unit. Collective social and cultural authority in tailored messages is 
perceived to bolster health communication and positively impact health outcome. 
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ABSTRACT
Introduction: Minority and underserved populations carry the largest cancer burden for the United States (ACS, 2016). Genetic counsel-
ing, testing and technologies show promise to help reduce cancer through personalized medicine opportunities however disproportions of 
genetic services, uptake and research about genetic testing among these populations exist (Ricker, et al., 2018). Inequitable cancer-related 
genetic and genomic testing (CGT) communication among minority and underserved populations and other barriers (e.g., genetic counselor 
bias) may contribute to CGT disparities. Exploring existing attitudes, perceptions and beliefs toward CGT among minority and underserved 
patient populations may bolster strategies to address communication inequities. The study aims were to explore an under-researched area of 
precision medicine, i.e., the communication of genetic risk factors among minority and underserved patient populations with high to moderate 
risk and disseminate and share findings with the community.
Methods: A Community Advisory Board comprised of researchers, cancer survivors and family members of cancer patients met from Decem-
ber 2018 - March 2019 to discuss research design and data collection. Six stratified focus group discussions (N = 53) were held March - May 
2019 where a pre-focus group survey was administered.
Results: Survey results show most had not talked to their doctor/health care provider about genetic testing (87%). African Americans (AA) 
and Latinos expressed a lack of awareness and knowledge about CGT and the importance of cultural tailoring.
Conclusion: Separate themes that emerged among Latinos included immigration status and language as barriers to CGT. Among AA, par-
ticipants were highly distrustful of medical personnel and expressed outrage about the lack of recommendation for CGT. 
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ABSTRACT
Introduction: Engaging in healthy behaviors is not always rewarding (e.g., carrot vs. cake). Neural models of healthy behaviors focus on the 
balance between reward and regulation brain regions. This pilot study examines the engagement of reward and regulation regions during 
the evaluation of food and nonfood cues before and after a guided imagery exercise targeting positive associations with food and regulation. 
Our long-term goal is to understand the interaction between positive associations with healthy foods and thinking about future rewards may 
influence healthy decision-making. The objective of the current study is to empirically test the combined effects of positive affect and positive 
episodic future thinking on brain activation.
Methods: The project examined the effect of positive affect and episodic future thinking guided imagery on brain activation in regulation and 
reward regions. Participants included individuals with a body mass index greater than 25 (n = 20).
Results: Functional neuroimaging showed reduced activation in regulation-related brain regions (i.e., dorsomedial prefrontal cortex) to 
healthy and unhealthy food following guided imagery.
Conclusions: These results suggest more efficient regulation-related brain activation after positive episodic future thinking guided imagery.
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ABSTRACT
Introduction: The Establishing Meaningful Patient-centered Outcomes With Relevance for patients with Polycystic Kidney Disease 
(EMPOWER PKD) initiative aims to engage PKD stakeholders and patients to learn about health priorities, insurance issues, and patient 
engagement.
Methods: We utilized semi-structured focus groups. We developed and pre-piloted a guide that allowed for both conversational flow and 
consistency in questions among groups. We audio-recorded each group and transcribed the conversations verbatim. We performed an induc-
tive thematic analysis. Two investigators completed all data coding independently and in duplicate. We compare the results of an ethnically 
diverse focus group to the other seven that mainly included Caucasian participants.
Results: 14 individuals participated in this part of the study. Of these, (64.2%) reported having PKD, and (14.2%) being caregivers. The mean 
age of participants was 48.8 (range 29 - 75) years. The group included 85.75% African American and 7.1% reported more than one race.
Conclusions: It was challenging to recruit this group and it required establishing a relation with community nephrologists and faith-based 
organizations leads. Multiple participants stated that they would not have participated if the group was not exclusively ethnically diverse as 
they fear that their opinion may be outnumbered by a Caucasian majority. Some discussed believing that PKD was a “white” disease. Many 
discussed hiding their diagnosis which affected their activation and engagement and came with unanticipated psychological impacts. Partici-
pants unanimously described lack of trust-worthy, easy to understand educational resources for minorities as a main barrier to engagement.
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ABSTRACT
Introduction: The highest rates of obesity in the U.S. are among black women with a prevalence of 54.8%. Psychosocial factors, such as 
stress from racism, have been proposed as contributors to this disparity, but the mechanisms are unclear. The objective of this study is to 
understand the relationship between race-related stress and food choice among black women.
Methods: Forty-five participants were asked to come in fasted for two appointments, randomized to the order of stress exposure in a within 
subject design. Forty images for each condition were collected from two validated picture sets (International Affective Picture set and Socio 
Moral Image Database). The images were shown in random order and contained either racially charged scenes (e.g., Ku Klux Klan) or non-
racially charged scenes (e.g., aggressive dog) matched on valence (pleasant vs. unpleasant) and arousal (physiologically stimulating). Food 
choice and food demand tasks were completed pre and post stress exposure. Participants were surveyed on their stress levels, past experi-
ences of racism, and trauma.
Anticipated Results: It is expected that preferences for unhealthy foods will be greater after race related stress exposure compared to the 
other stress condition. We anticipate that those who have higher BMI’s are more likely to be affected in their changes in eating behaviors in 
both stress exposure states, with a larger impact from the race related stress induction. Data collection is ongoing.
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ABSTRACT
Introdution: To examine the impact of residential distance and socioeconomic status on survival outcomes for patients receiving treatment 
for ovarian cancer at an NCI-CC.
Methods: Patients who were treated for ovarian cancer at a single institution from 2010 - 2015 were identified. Age at diagnosis, insurance 
status, and distance from the patient’s home to the institution were abstracted. Clinical data including stage at diagnosis, surgical status, 
chemotherapy cycles, dates of diagnosis, recurrence, and death were obtained. Patients treated at other institutions and those with non-
epithelial pathology were excluded. Patients were stratified into three groups based on distance from the institution. Overall survival (OS) 
and progression free survival (PFS) were generated by Kaplan Meier survival curves and Cox proportional hazard models using SAS v9.4.
Results: Two hundred and three patients were identified. Survival analysis based on distance demonstrated that patients who lived less than 
10 miles from the institution have worse survival (p = 0.0412). Lower median income (< 56,179) regardless of distance to institution was also 
associated with worse survival, p = 0.0283. After adjusting for stage of disease, age at diagnosis, surgery status, chemotherapy resistance, 
income quartile and presence of comorbid conditions, distance < 10 miles from the institution was still a significant predictor of worse overall 
survival, HR 2.62 95% CI (1.333 - 5.142), p = 0.0052.
Conclusion: Among patients who received guideline-adherent care for ovarian cancer, lower median income and residential distance less 
than 10 miles to an NCI-CC was associated with worse overall survival. 
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ABSTRACT
Introduction: The shooting of unarmed citizens by police officers is a topic at the forefront of public awareness. The disproportionate rate at 
which unarmed Black citizens are shot is believed to reflect widespread racial bias on behalf of officers, which erodes public trust and reduces 
policing effectiveness.
Methods: We have developed an Attention-integrated Model-based Shooting Simulator (AiMSS) to gain a deeper understanding of the 
mechanisms underlying the decision to shoot. The AiMSS combines computational models of decision making, visual psychophysics and 
eye-tracking methods, and an immersive decision simulator to map the processes police officers use to decide to shoot.
Results: Results with the AiMSS reveal that policing scenario and suspect behavior accounted for the most variation in decisions. Process 
level measures show little evidence of an initial bias to shoot Black suspects. Instead, results reveal a diminished ability to distinguish objects 
held by Black suspects.
Conclusions: This work emphasizes the importance of contextual factors in the decision to shoot and highlights how past experimental 
studies on racial bias have neglected critical inputs into officer deadly force decisions.
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ABSTRACT
The Emerging Imaging Technologies and Applications Laboratory (EITAL) is a shared resource serving as a proof-of-concept hub for 
performing innovative and rigorous fundamental cancer biology research at subcellular to cellular length-scales in conjunction with the 
development and translation of advanced imaging technologies and applications. The scientific staff of EITAL are experts in developing and 
improving reagents, methods, and optical and electron microscopic imaging technologies, antibody development, screening, and character-
ization, immunohistochemistry, immunocytochemistry, correlative optical and electron microscopy, immunoelectron microscopy, workflow 
development, and experimental design and data analysis of imaging studies. EITAL promotes synergies between its imaging technology 
developers and University of Kansas Cancer Center (KUCC) cancer biology researchers. EITAL also provides research training and career 
development programs to ensure a talented and diverse workforce engaged in cellular tumor cancer biology imaging research. The collabo-
ration between EITAL and the University of Kansas (KU) Microscopy and Analytical Imaging Research Resource Core Laboratory (MAI) 
imaging scientists, enables imaging research at the level of the whole animal, individual cells, as well as molecules inside the cells, and provides 
instrumentation and expertise for optical and electron microscopies, resulting in multi-scale/multi-dimensional correlative imaging research 
of living and fixed cells and tissues. The KUCC Support Grant (P30 CA168524) supports EITAL.
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ABSTRACT
Introduction: Sensorimotor integration deficits are common in Autism Spectrum Disorders (ASD). Evidence exists for an over-reliance on 
both visual and proprioceptive feedback during motor control in ASD, suggesting deficits in the modulation of sensory feedback processing 
and inability to use the most reliable input. This study aims to test this hypothesis.
Methods: Forty persons with ASD (10 - 33 yrs) and 25 age-, sex- and nonverbal IQ-matched controls completed precision gripping tasks. 
They squeezed a force sensor with their index finger and thumb and tried to match their force output to a target force. Visual feedback was 
presented on a computer screen across low, medium, and high gain levels; the force output bar moved a greater distance per change in force at 
higher gains. A stationary bar represented the target force. 80Hz tendon vibration was applied at the wrist to create a proprioceptive illusion 
of muscle contraction. Force regularity (approximate entropy; ApEn) was examined.
Results: Preliminary results from 18 participants with ASD and 13 controls indicate a Group x Tendon Vibration x Visual Gain interaction 
for ApEn (F = 1.559, p = 0.023). Controls showed increased ApEn during 80Hz tendon vibration at low visual gain but decreased ApEn with 
vibration at high visual gain. Individuals with ASD show slight increases in ApEn with 80Hz vibration across visual conditions. 
Conclusions: Early findings indicate that controls shift to a secondary source of sensory feedback (e.g., proprioception) when the primary 
source (e.g., vision) is degraded. Persons with ASD fail to dynamically recalibrate feedback processes across sensory systems when feedback 
conditions change.
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ABSTRACT
Introduction: African American women experience higher incidence and mortality rates of cervical and breast cancer. The purpose of this 
study is to develop and implement a breast and cervical cancer screening intervention to increase awareness, uptake of screening, and follow-
up among an African American female church-population in Sedgwick County, Kansas.
Methods: Academic researchers recruited local pastors (N = 11) to develop a faith taskforce. Using intervention mapping, we conducted three 
focus groups with the taskforce to assess barriers and facilitators to seeking breast and cervical screenings and multi-component strategies to 
improve education and awareness of breast and cervical cancer screening recommendations, screening rates, and follow-up among African 
American women.
Preliminary Results: Of the 11 faith taskforce pastors, three were females. The key identified themes focused on barriers and facilitators to 
implementation of church-based cervical/breast cancer interventions, such as time constraints, limited expertise in conducting faith-based 
interventions, and lack of awareness on burden of cancer in the community, awareness of screening recommendations, and support/account-
ability in cancer screening and follow-up. Participants also indicated that a mobile phone app to track screenings, follow-up appointments, 
and promote education about risk factors and a church health navigator to assist with app utilization and track screenings and follow-up 
appointments would need to be primary intervention components.
Conclusions: Findings from the taskforce focus groups highlight the need for multi-component church-based interventions that include a 
mHealth app and church health navigators to improve awareness and adherence to breast/cervical cancer screening recommendations and 
follow-up among African American female church populations.
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ABSTRACT
Introduction: Rituximab (RTX) is an effective maintenance therapy in forms of ANCA-associated vasculitis (AAV), specifically granulo-
matosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (MAINRITSAN trial). Sixteen percent of patients will relapse despite 
RTX. Infliximab, an anti-chimeric antibody like RTX, is associated with a high rate of anti-drug antibody formation which effects its efficacy. 
The aims of this study are to a) evaluate the incidence of immunogenicity toward rituximab in AVV; and b) evaluate the relationship between 
anti-RTX antibodies and drug response. Herein we present the baseline data.
Methods: Inclusion criteria: a) meet either 1990 ACR and/or 2012 revised CHCC criteria for GPA or MPA; b) remission at entry; c) received 
Rituximab in last 12 months; d) plan to continue Rituximab; and e) no contraindications for receiving further RTX infusions. 
Results: 30 participants (25 GPA and 5 MPA) were enrolled. ANCA by EIA was MPO positive in 14 (47%), PR3 positive in 13 (43%) and 
negative in 3 (10%). Mean age at enrollment was 62.5 years (IQR 46.5 - 67.5). 70% were female. The average immunoglobulin G (IgG) at 
baseline was 663 mg/dl (95% CI 566 - 760). 67% of participants had undetectable B-cells at baseline. Average time between the last Ritux-
imab infusion and the first study Rituximab infusion was 34 weeks (95% CI 28 - 40 weeks).
Conclusions: At study baseline most of the participants were found to be B-cell depleted and mildly hypogammaglobulinemic. The average 
duration since the last Rituximab infusion at entry (8.5 months) was slightly longer than in the MAINRITSAN trial (six months).
Funding Support: This work was supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of 
Kansas Clinical and Translational Science Institute (#UL1TR002366). The contents are solely the responsibility of the authors and do not 
necessarily represent the official views of the NIH or NCATS.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.
org/licenses/by-nc-nd/4.0/)
KANSAS JOURNAL of  M E D I C I N EJeffrey Statland, M.D.
Assistant Professor
Department of Neurology
University of Kansas Medical Center
Institute for Advancing Medical Innovation (IAMI) Trailblazer Award Recipient
Open-Label Pilot Study of Ranolazine for Cramps in Amyotrophic Lateral Sclerosis
Received Feb. 7, 2020; Accepted for publication Feb. 10, 2020; Published online Feb. 26, 2020
ABSTRACT
Objective: To determine safety and tolerability of two doses of ranolazine in patients with ALS and evaluate for preliminary evidence of 
drug-target engagement.
Background: Ranolazine, an FDA-approved drug for angina which inhibits the late Na+ current and intracellular Ca2+ accumulation, may 
be neuroprotective in ALS and reduce cramp frequency by reducing neuronal hyperexcitability. 
Design/Methods: Open-label dose-ascending study of ranolazine with 12 participants in two sequential cohorts: 500 mg and 1,000 mg 
orally twice daily. Each has a two-week run-in period, four-week drug administration and six-week safety follow up. Primary outcome is the 
frequency of dose limiting toxicities and adverse events. Exploratory measures include cramp frequency and severity, fasciculation frequency 
(on ultrasound), cramp potential duration, ALS Functional Rating Scale-revised (ALSFRS-r), and forced vital capacity (FVC) compared 
from baseline to week six.
Results: The 10 currently enrolled patients (Cohort 1, n = 6; Cohort 2, n = 4) are mostly male (80%), and middle aged (median 53 years). 
There were no serious adverse events. One subject in cohort 2 discontinued the drug due to constipation. The most frequent drug-related 
adverse event was gastrointestinal (38%). Cramp frequency reduced by 44% (p = 0.01) and severity decreased by 36% (p = 0.002), with 
decreased awakening due to cramps and cramps interfering with daily activities or causing activity avoidance. Fasciculations, cramp potential 
duration, ALSFRS-r and FVC did not change.
Conclusion: Ranolazine was well tolerated in ALS up to 2,000 mg daily with gastrointestinal side effects being the most frequent. Ranolazine 
reduced cramp frequency and severity without significant effect on fasciculations, ALSFRS-r or FVC.
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ABSTRACT
Dietary intake of fruits and vegetables is consistently related to chronic disease risk. Unfortunately, measurement of fruit and vegetable 
intake is most often by self-report and thus, there are concerns about the validity of the data. The Veggie Meter (VM) uses Resonance 
Raman light scattering spectroscopy (RRS) to non-invasively measure skin carotenoid content. Skin carotenoids have recently been 
reported as a reproducible and valid biomarker for dietary intake of fruits and vegetables. In August of 2017, we purchased a VM and began 
using it in several studies. Due to demand, we were unable to accommodate all studies. Thus, in July 2018 Frontiers provided funds to pur-
chase another VM. To date, we have used VM in seven completed pilot studies (six interventions and one observational study) and are using 
it in three ongoing studies. Specifically, the Frontiers-purchased machine is being used in two NIH-funded clinical trials. It is also used in 
community outreach events. The average age of individuals screened using this VM is 74.9 years and the VM score is 281.9 ± 70.1, indicat-
ing poor intake similar to the national average. Within 54 healthy older adults, VM scores correlated with intake of vegetables (r2 = 0.2, p 
= 0.001), fruits and vegetables (r2 = 0.15, p < 0.01), and four individual carotenoids (r2 > 0.18 & p < 0.01 for all) derived from self-reported 
3-day food records. The VM is quick, non-invasive, and easy to use. It provides an objective measure of fruit and vegetable intake and will 
continue to be incorporated into our nutrition clinical trials and observational studies.
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ABSTRACT
Objective: Greater cognitive function (CF) is associated with adherence to prescription medications, better program adherence and weight 
loss (WL) following bariatric surgery. The purpose of this study was to evaluate the association between baseline CF, intervention dropout, 
adherence and three-month WL.
Methods: One hundred and seven (Mean age = 40.9 yrs.), overweight/obese (BMI = 35.6 kg/m2) men (N = 17) and women (N = 90) com-
pleted a three-month WL intervention. Participants were asked to attend weekly behavioral sessions, comply with a reduced calorie diet 
and complete 100 min of moderate intensity physical activity (PA)/wk. CF tasks including Flanker (attention), Stroop (Executive control) 
and working memory, body weight and cardiovascular fitness (covariate) were assessed at baseline and three-months. Session attendance, 
adherence to PA and diet prescriptions and number of off-diet episodes were recorded weekly.
Results: Results indicated that attention was positively correlated with session attendance (p = 0.016), adherence to the diet (p < 0.01) and PA 
(p = 0.023). Executive control was positively correlated with WL (p = 0.042). Working memory (two tasks) was also positively correlated with 
WL (p = 0.017 and p = 0.025). Analysis of variance (ANOVA) indicated that baseline attention (p = 0.012) was positively related to WL and 
negatively associated with drop out (p < 0.05). Hierarchical linear regression showed executive control (p = 0.036, R2 = 0.054) and working 
memory (p = 0.013, R2 = 0.073 and p = 0.017, R2 = 0.068) were associated with WL when controlling for fitness.
Significance: These results suggest that stronger baseline attention is associated with completion of a three-month WL intervention. Execu-
tive control and working memory are associated with amount of WL achieved. Additional, larger and longer trials to assess the role of baseline 
CF on WL and evaluating the impact of interventions designed to improve CF on WL are indicated.
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ABSTRACT
Introduction: Adolescent mothers are less likely to initiate and sustain exclusive or partial breastfeeding. About 70% of mothers under age 20 
initiate breastfeeding, compared to 80% of 20 - 29-year-old mothers. Duration of breastfeeding to six months and one year by young mothers 
is 28% and 18%, compared to 48% and 28% in 20 - 29-year olds. Early breastfeeding experiences can adversely influence duration of breast-
feeding. This study describes the early postpartum breastfeeding experiences among mothers 16 - 19 years of age. 
Methods: This is a descriptive study within a larger pilot clinical trial.  Four to eight weeks after giving birth, participants completed the Breast-
feeding Experience Scale (BES), a 30-item measure which documents breastfeeding experiences, feeding patterns, and weaning. Severity of 
18 early experiences are rated on a Likert type scale of 1 - 5 (1 = “not at all” to 5 = “unbearable”). Cronbach’s alpha for the 18-item summated 
scale of the BES was 0.80. Descriptive statistics characterized experiences for this in-progress study. 
Results: Thirty breastfeeding participants, ages 16 - 19 (X = 17.97, SD = 0.96) completed the BES. Twenty-one (70%) were breastfeeding at 
time of survey and 57% were doing so exclusively. The most frequently reported breastfeeding problems were engorgement and leaking which 
were rated mild to moderate in severity (X = 2.97, SD = 1.03). Nine mothers (30%) weaned between 14 and 30 days after birth; engorgement, 
latching difficulty, and drop in milk supply were most common reasons. 
Conclusions: Most teenage mothers in this sample maintained breastfeeding past one month after birth and reported few problems.
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ABSTRACT
Introduction: Obesity affects ~14 million children/adolescents in the U.S. (8.9% of 2 - 5-year-olds; 17.5% of 6 - 11-year-olds) and increases the 
risk of developing type 2 diabetes (T2DM). Early metformin intervention may delay or halt progression to T2DM. However, clinical response 
to metformin in children with insulin resistance or T2DM is unpredictable. Additionally, no dosing recommendations exist for children < 10 
years. Preliminary data show that clinical response to metformin may depend on the amount of metformin present in the body over time (sys-
temic exposure), with maximum response observed at exposures = 30 mg/L*h. Modelling and simulations can help determine individualized 
doses to achieve this exposure, ideally achieving favorable response for every patient. This study aims to prospectively validate simulations of 
the metformin dose-exposure relationship in young children.
Methods: A 24-hour pharmacokinetic study (measuring systemic exposure) of 500 mg metformin in children (6 - 12 years) with IR. 
Pharmacokinetic simulations including individual parameters (e.g., sex, age, weight) were conducted for each subject using Simcyp, a physi-
ologically-based pharmacokinetic simulator.
Results: Two out of 12 subjects have completed the research study: Subject 1: Female, 12 years, 158.6 cm, 70.2 kg, BMI: 97.44 percentile, 
HbA1C: 6.7%; simulation-recommended dose: 1750 mg. Subject 2: Male, 8 years, 134.9 cm, 36.5 kg. BMI 95.58 percentile, HbA1C: 6.5%; 
simulation-recommended dose: 1100 mg. Clinical pharmacokinetic data is not yet available. 
Conclusion: Individualized doses of metformin may benefit young children with IR. Smaller/younger patients may require smaller doses of 
metformin than larger/older children; clinical pharmacokinetic data is needed to support simulation-guided individualized dosing.
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ABSTRACT
Introduction: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and has one of the worst one-year survival 
rates of any cancers. Understanding molecular mechanisms leading to HCC and developing novel strategies for effective prevention and 
treatment are urgent medical needs. HCC arises exclusively on the background of chronic liver injury and inflammation. Thus, an attractive 
therapeutic approach is to target key genes that regulate both inflammation and oncogenic pathways in HCC. RNA-binding protein Hu Antigen 
R (HuR) is one such candidate that controls the translation of multiple genes involved in inflammation and oncogenic process. The objective 
of this study is to characterize HuR targets in human HCC and test HuR-targeted intervention for HCC treatment.
Methods: HuR knockout (HuR-KO) in HCC cell line MHCC97H cells was accomplished by CRISPR/Cas9 gene editing system. The tran-
scriptome comparison identified 1,516 differentially-expressed genes between HuR-KO cells and wild type controls. The top pathways altered 
by HuR knockout were cell proliferation, hippo signaling, beta integrin, pluripotent stem cells, EGFR, WNT, and FAK-PI3K-Akt-mTOR. To 
test HuR-targeted intervention for HCC treatment in vivo, MHCC97H cells were subcutaneously injected into athymic nude mice to establish 
HCC xenografts. Mice were then treated with a novel synthetic HuR inhibitor KH-3 for four weeks.
Results and Conclusions: Strikingly, KH-3 treatment significantly inhibited the growth of HCC xenografts. Taken together, our study 
provides a foundation for understanding the role of HuR in HCC. The mechanistic insights elucidated from our study may pave the way for 
developing therapeutic strategies to specifically target HuR for HCC treatment.
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